|
Primary Care
| | | | | | | | |
|
Bloom
|
2017
|
Australia
|
Prospective cohort study of treatment uptake and SVR
|
Adherence to DAA treatment protocols
|
Treatment by tertiary care provider
|
1044
|
503 (40.6)
|
253 (50.2)
|
|
Francheville
|
2017
|
Canada
|
Prospective observational study design
|
Specialist nurse-led care
|
No comparator group
|
242
|
93 (38.4)
|
82 (88.2)
|
|
Kattakuzhy
|
2017
|
USA
|
Non-randomised open label study
|
Treatment by primary care providers (PCP) and nurse practitioners (NP)
|
Standard care - Treatment by secondary care clinic
|
NP 150 PCP 160
| |
NP 134 (89.3) PCP139(86.9)
|
|
McCLure
|
2017
|
Australia
|
Retrospective data analysis of SVR12
|
Nurse-led care and GP remote consultation
|
Specialist care in Tertiary centre
|
Nurse-led 70
|
50 (74.3)
|
46 (65.7)
|
|
Miller
|
2016
|
USA
|
Retrospective observational study
|
Treatment by primary care providers
|
No comparator group
|
95
| |
79 (83)
|
|
Norton
|
2017
|
USA
|
Retrospective cohort study of SVR
|
Treatment in urban primary care centre
|
SVR 12 in PWIDs and non_PWIDs
|
89
| |
85(95.5)
|
|
Wade
|
2018
|
Australia
|
Randomised controlled trial
|
Testing, assessment and treatment in primary care
|
Testing, assessment and treatment in tertiary care
|
59
|
31 (52.5)
|
14 (23.7)
|
|
Integrated Health Systems (ECHO)
| | | | | | | | |
|
Abdulameer
|
2016
|
USA
|
Retrospective data analysis of SVR 12
|
VA-Echo model supporting primary care providers
|
No comparator group
|
588
| |
318 (54)
|
|
Beste
|
2017
|
USA
|
Retrospective cohort study of treatment uptake and SVR
|
VA-Echo model supporting primary care providers
|
Standard care - Treatment by unexposed primary care providers
|
6431
|
1303 (21.4)
|
(58.2)
|
|
Buchanan
|
2015
|
United Kingdom
|
Retrospective data analysis
|
Community-based outreach clinic
|
Standard care - Treatment by secondary care clinic
|
77
|
24 (31.2)
| |
|
Georgie
|
2016
|
USA
|
Retrospective data analysis of SVR12
|
VA-Echo model supporting primary care providers
|
Treatment by sub-specialist providers
|
623
| |
Genotype 1 (GT1) (99) GT2 (98) GT3 (79)
|
|
Opioid Treatment Centres
| | | | | | | | |
|
Butner
|
2017
|
USA
|
Retrospective data analysis
|
Opioid treatment programme
|
No comparator group
|
75
|
75.0
|
64 (85.0)
|
|
Morris
|
2017
|
Australia
|
Retrospective data analysis of treatment uptake and SVR
|
Treatment in a community-based harm reduction and treatment facility
|
No comparator group
|
127
|
122 (96)
|
102 (80.3)
|
|
Read
|
2017
|
Australia
|
Retrospective data analysis of SVR12
|
Treatment of PWIDs in primary care setting
|
No comparator group
|
72
| |
59 (81.9)
|
|
Pharmacies / Pharmacist Clinics
| | | | | | | | |
|
David
|
2017
|
USA
|
Retrospective data analysis of SVR12
|
Pharmacy-managed clinics
|
Treatment by non-pharmacist providers
|
204
| |
(83.6)
|
|
Radley
|
2017
|
United Kingdom
|
Pilot cluster RCT of treatment uptake and SVR
|
Treatment in community Pharmacy
|
Treatment by secondary care clinic
|
26
|
3 (11.5)
|
3 (11.5)
|
|
Telemedicine
| | | | | | | | |
|
Cooper
|
2017
|
Canada
|
Retrospective cohort study of treatment uptake and SVR
|
Use of telemedicine
|
Treatment by secondary care clinic
|
157
|
35.0
|
18 (11.5)
|
